Background/Aims: The goal of this study was to detect the expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) in human retinal pigmented epithelial (RPE) cells treated with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, under hypoxic and normoxic conditions and to explore the signaling mechanism involved in regulating the hypoxia-induced expression of HIF-1α and VEGF in RPE cells. Methods: D407 cells were cultured in normoxic or hypoxic conditions, with or without celecoxib or a PI3K inhibitor (LY294002). The anti-proliferative effect of celecoxib was assessed using the MTT assay. RT-PCR, Western blotting and ELISA were performed to detect the levels of PI3K, phosphorylated AKT (p-AKT), HIF-1α, VEGF and COX-2. Results: Celecoxib inhibited the proliferation of RPE cells in a dose-dependent manner. Celecoxib suppressed the expression of VEGF at both the mRNA and protein levels and decreased HIF-1α protein expression. HIF-1α activation was regulated by the PI3K/AKT pathway. The celecoxib-induced downregulation of HIF-1α and VEGF required the suppression of the hypoxia-induced PI3K/AKT pathway. However, the down-regulation of COX-2 did not occur in cells treated with celecoxib. Conclusions: The antiangiogenic effects of celecoxib in RPE cells under hypoxic conditions resulted from the inhibition of HIF-1α and VEGF expression, which may be partly mediated by a COX-2-independent, PI3K/AKT-dependent pathway.
Introduction
Choroidal neovascularization (CNV) is a major characteristic of wet age-related macular degeneration (AMD) and is one of the most common causes of irreversible blindness in people over 60 years old in western countries [1] . Recent studies indicate that CNV is
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This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. a complex process in which the degeneration of retinal blood vessels in the elderly leads to tissue ischemia and hypoxia; therefore, hypoxia-mediated signaling is thought to be involved in the progression of the wet form of AMD [2] . A key transcriptional regulator of the hypoxic response is hypoxia-inducible factor (HIF), which consists of HIF-1α and HIF-1β subunits. HIF-1α is regulated by oxygen tension, whereas HIF-1β is constitutively expressed. Studies have indicated that HIF-1α is an important oxygen sensor and plays a crucial role in vasculogenesis and angiogenesis. A particularly key HIF-1α responsive gene, VEGF, encodes its transcriptional activity [3] . VEGF, a specific mitogen for endothelial cells, has been identified as a key mediator in the retina and CNV [4] . A number of studies have observed that retinal pigment epithelial (RPE) cell-derived VEGF plays a key role in the progression of CNV [5] [6] [7] . VEGF is also increased in the vitreous and CNV membranes of patients with AMD [6, 8] . Based on these data, current anti-VEGF therapies have become effective primary treatments for neovascular AMD [9] . However, repeated intravitreal injections of anti-VEGF drugs (e.g., ranibizumab, bevacizumab) increase the risk of side effects, which have a high clinical cost [10, 11] . With an efficiency of 60%-70% and disease progression still occurring in some patients receiving anti-VEGF treatment, the retinal VEGF levels are still not altered [12] . Thus, there may be other causative agents affecting VEGF expression in CNV.
The expression of VEGF can be induced by multiple cellular pathways. Hypoxia results in the expression of HIF-1α, which, in turn, induces VEGF expression. It is generally accepted that hypoxia regulates CNV through the induction of HIF-1α and VEGF [13, 14] . However, few studies have been conducted investigating the upstream signaling events activated by hypoxia and its effects on CNV. It has been well demonstrated that the serine/threonine kinase AKT is one of the primary upstream regulators of HIF-1α, and this signaling pathway plays a key role in cell proliferation, transformation, survival, tumor angiogenesis and growth. AKT is activated by a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway [15, 16] . The accumulation of HIF-1α protein and other cytokines during hypoxia are involved in the activation of the PI3K/AKT pathway. In hypoxic tumor cells, HIF-1α expression can be facilitated by PI3K/AKT signaling. Abnormal PI3K/AKT signaling may result in increased or uncontrolled cell proliferation in tumors [17] .
One possible candidate for disrupting the angiogenic signaling cascade upstream of HIF-1α-VEGF expression is celecoxib, a Cox-2-selective inhibitor that has efficacy equivalent to that of non-selective NSAIDs but presents with fewer adverse gastrointestinal events [18, 19] . Celecoxib presents with anti-inflammatory, anti-tumor and anti-angiogenic properties. One study found that celecoxib reduced VEGF production through the PI3K/AKT/HIF-1α pathway in a murine hepatocarcinoma model [19] and induced apoptosis via the down-regulation of PI3K/AKT [20, 21] . In ophthalmology, celecoxib has been experimentally shown to suppress VEGF expression in the cornea, the retina and CNV and to effectively reduce angiogenesis [22] [23] [24] . Celecoxib also has anti-proliferative effects in RPE cells, and it can cause cell cycle arrest, which provides a strong rationale for the use of celecoxib in the treatment of AMD [25] . However, the mechanisms, the target molecules and the role of the PI3K/AKT/HIF-1α pathway in CNV remain unknown. We hypothesized that celecoxib reduces VEGF levels thought the PI3K/AKT/HIF-1α pathway in CNV. The purpose of this study was to examine the expression of related factors in RPE cells under normoxic and hypoxic conditions and to determine whether celecoxib treatment can suppress the expression of VEGF by inhibiting the PI3K/AKT/HIF-1α pathway in CNV.
Materials and Methods
Cell culture and hypoxic treatment Human RPE D407 cells were purchased from the Central Laboratory of Xiangya Central South University, China and were cultured in DMEM medium supplemented with 10% FBS (heat inactivated), 1% nonessential amino acids, 20mM HEPES, 29mM sodium bicarbonate, 100U/ml of penicillin and 100μg/ml of streptomycin. All cells were cultured in T-25 flasks and maintained in a humidified atmosphere of 5% CO2 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays
The MTT assay was performed to determine the effect of celecoxib on the growth of D407 cells under normoxic or hypoxic condition. Cells were seeded at 1 ×10 4 cells/well in 96-well plates and were continuously cultured for 24 hrs; then, the cells were subjected to hypoxia and cultured with medium supplemented with 1, 10, 20, or 25 μM celecoxib for an additional 12 hrs. Thereafter, each well was supplemented with 20 μL of MTT (5 g/L) (Sigma-Aldrich, USA) and incubated for an additional 4 hrs. The blue formazan produced was solubilized with dimethyl sulfoxide (DMSO, 200 μl/well), and the absorbance was measured at 570 nm by a spectrophotometer. The inhibition of cell growth was calculated according to a published formula [26] .
RNA isolation and reverse-transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells treated with or without hypoxia by TRIzol reagent (Life Technologies, Glasgow, UK) as described in the manufacturer's protocol. Semi-quantitative RT-PCR assays have been described previously. Reverse transcription was performed with approximately 0.5 μg of total RNA, reverse transcriptase (SuperScript II; Life Technologies, Gaithersburg, MD, USA) and 5.0 μM oligo-d(T) primer. Aliquots of cDNA were used for PCR amplification with primers specific for HIF-1α, VEGF and β-actin. The primer sequences were as follows: VEGF (421 bp) 5'-CCTTGCTGCTCTACCTCC-3' and 5'-AAATGCTTTCTCCGCTCT-3'; HIF-1α (434 bp): 5'-GAAACCACCTATGACCTGC-3' and 5'-CTGTTTGTTGAAGGGAGAA-3'; and β-actin (472 bp): 5'-AAATCGTGCGTGCGTGACATTAA-3' and 5'-CTCGTCATACTCCTGCTTG-3' (Dalian Bao Bio Co., Ltd., China). Standard PCR amplification was performed as follows: 94°C for 5 min, 35 cycles of denaturation at 94°C for 45 sec, 58°C for 50 sec, and 72°C for 40 sec and 10 min at 72°C. The amplified products were visualized on 1% agarose gels. The electrophoretic bands were determined with 100 bp gradient markers (Dalian Bao Bio Co., Ltd., China). The expression levels of target gene mRNA were calculated by normalizing the absorbance of the target gene to that of β-actin.
Western blot analysis
Cells were treated with celecoxib or LY294002 and exposed to normoxic or hypoxic conditions for the indicated durations. The cells were collected in radio immunoprecipitation assay (RIPA) buffer and incubated on ice for 30 min. The total protein concentration was measured by a BCA Protein Assay Kit-23227 (Pierce Biotechnology). Protein samples (50 μg) were subjected to 10% SDS-PAGE and transferred to PVDF membranes (Hybond-C, Amersham and Piscataway, New Jersey, USA). The membranes were blocked with 5% (w/v) nonfat milk and probed with rabbit anti-human polyclonal antibody (PI3K 1:400, phospho-AKT 1:400, AKT 1:500, VEGF, 1:300, HIF-1α, 1:200, and Cox-2 1:400; Santa Cruz Biotechnology, USA) and mouse anti-human β-actin monoclonal antibody (1:400) at 4°C overnight. The membranes were incubated with goat anti-rabbit alkaline phosphatase-labeled antibody or horse anti-mouse IgG antibody (Santa Cruz, CA, USA). All experiments were repeated in triplicate. Immunoreactive strips were identified using a DAB system (DAB Kit-0031; Maixin Biotechnology Corporation, China) according to the manufacturer's instructions. A bioimaging system (UVP, Upland, CA, USA) was used to capture specific bands, and the optical density (OD) of each band was measured using ImageJ software. The ratio of the OD of the protein of interest and that of β-actin in each sample was calculated as the relative content and expressed graphically.
Enzyme-linked immunosorbent assay
Cultures of RPE cells were grown to confluence and treated with 20 μM celecoxib for 12 hr in normal or hypoxic conditions. The levels of HIF-1α and VEGF in the culture supernatants were determined using a VEGF and HIF-1α ELISA kit (R&D Systems, USA) according to the manufacturer's instructions 
Results

Effect of celecoxib on D407 cell proliferation
Hypoxia-mediated cell proliferation is one of the critical factors involved in neovascularization. Thus, we evaluated RPE cell proliferation in the presence of different concentrations of celecoxib (1, 10, 20, or 25 μM) under normoxic or hypoxic conditions for 12 hr. As shown in Fig. 1 , the cell proliferation of D407 cells at 10, 20, and 25 μM celecoxib was lower than that at 1 μM celecoxib (P < 0.01). Celecoxib (20 and 25 μM) significantly inhibited hypoxia-induced proliferation compared to the proliferation observed under the normoxic condition (p < 0.01).
Hypoxia increased HIF-1α and VEGF mRNA expression and the effects of celecoxib on HIF-1α and VEGF activation
The mRNA expression levels of HIF-1α and VEGF were examined under normoxic and hypoxic conditions for 3, 6, and 12 hr. A significant increase in HIF-1α and VEGF mRNA expression was detected , and 12 h. The total RNA isolated from RPE cells was measured by RT-PCR analysis with HIF-1α and VEGF specific primers, and β-actin was used as the internal control. B The quantified data indicate that hypoxic treatment for 3 hr to 12 hr significantly increased the mRNA expression levels of HIF-1α and VEGF compared with these expression levels in the normoxic group. *p< 0.05, **P< 0.01 compared with normoxia. Statistics: one-way ANOVA with Bonferroni correction. after exposure to the hypoxic condition for 3 to 12 hr (Fig. 2) . Since the expression levels were substantially elevated after exposure to hypoxia for 12 hrs, 12-hr incubations were used for the following experiments.
To verify whether celecoxib can suppress the hypoxia-induced increase in HIF-1α and VEGF levels, cells were exposed to normoxic and hypoxic conditions with or without celecoxib treatment (10 or 20 μM) for 12 hr, and the expression levels of HIF-1α and VEGF were detected by RT-PCR analysis. Celecoxib did not alter the mRNA expression of HIF-1α; however, in D407 cells, it significantly reduced the mRNA levels of VEGF in a concentrationdependent manner (Fig. 3) .
Celecoxib inhibits HIF-1α protein accumulation by suppressing PI3K/AKT signaling
We evaluated whether PI3K/ AKT signaling is involved in hypoxia-induced HIF-1α activation. As shown in Fig. 4 , the level of p-AKT was elevated when RPE cells were cultured in hypoxia for 12 hrs, whereas HIF-1α protein expression was increased, suggesting that hypoxia increased both HIF-1α and p-AKT expression levels. We also investigated whether the PI3K/AKT signaling pathway was involved in the hypoxia-induced increase in HIF-1α in RPE cells by treating cells with 20 μM LY294002 (a PI3K inhibitor) for 12 hr under hypoxia. LY294002 significantly inhibited the increase in HIF-1α expression in RPE cells exposed in hypoxia (Fig. 4) . The data demonstrated that under hypoxic conditions, PI3K/ AKT signaling may be an upstream regulator of HIF-1α expression in RPE cells. In addition, to verify that PI3K/AKT signaling contributes to the celecoxib-induced decrease in HIF-1α and VEGF expression, Western blot analysis was performed to assess the activation of PI3K, p-AKT, HIF-1α and VEGF in RPE cells treated with or without 20 μM celecoxib under hypoxic conditions for 12 hr. As shown in Fig. 5 , in RPE cells exposed to hypoxia for 12 hr, celecoxib markedly suppressed the protein expression levels of PI3K, p-AKT, HIF-1α and VEGF compared to these expression levels in cells under normoxic conditions, indicating that celecoxib treatment suppressed the activation of this pathway and diminished the protein levels of HIF-1α and VEGF.
Modulation of COX-2 expression in RPE cells treated with celecoxib is through the PI3K/ AKT pathway
To examine if under hypoxic conditions, celecoxib induced the down-regulation of HIF-1α and VEGF protein levels through a COX-2-independent PI3K/AKT pathway we investigated the protein expression of COX-2 under normoxic and hypoxic conditions in the absence or presence of LY294002, celecoxib or LY294002 combined with celecoxib. As shown in Fig. 6 , compared to the expression in normoxic conditions, exposure to hypoxia for 12 hr resulted in a marked increase in COX-2 protein expression. Meanwhile, compared with hypoxia, treatment with LY294002 caused a greater increase in COX-2 expression. Surprisingly, the up-regulation of COX-2 protein expression was not impaired in cells treated with celecoxib, which indicated that the down-regulation of HIF-1α through the PI3K/AKT pathway is independent of COX-2. The results were in accordance with a study by Monick et al. that found that PI3K suppression led to an increase in COX-2 protein expression since PI3K negatively regulates the activation of the p38 pathway [27] . Thus, celecoxib may up-regulate COX-2 expression by down-regulating PI3K.
Estimation of HIF-1α and VEGF Secretion in RPE Cells by ELISA
A marked increase in the secretion of HIF-1α and VEGF was detected in RPE cells exposed to hypoxia for 12 hrs. Compared with the levels in hypoxia, treatment with 20 μM celecoxib significantly decreased the secretion of HIF-1α and VEGF (Fig. 7) .
Discussion
Hypoxia plays a central role in the development and progression of ocular vascular disease. Hypoxia results in the expression of HIF-1α, which regulates VEGF up-regulation under hypoxic conditions [28, 29] . RPE cells can activate the HIF-1α pathway to release VEGF, initiating angiogenesis in CNV [30, 31] . A large number of studies have been conducted to identify inhibitors of the HIF pathway in RPE cells. Lin et al. knocked out HIF-1α in the RPE using the cre/lox system and suggested that RPE-derived HIF-1α plays a critical role in CNV [32] . Kurihare et al. demonstrated the off-target effects resulting from the specific knockout of the VEGF gene in adult mice. These knockout mice exhibited degeneration of the choriocapillaris, dysfunctional cone photoreceptors, and ultimately vision loss. However, transcriptional HIF mutants did not elicit any marked secondary off-target effects [33] . The evidence suggests that for the treatment of ocular neovascular diseases, therapeutics targeting the HIF pathway may be an safer, more effective alternative mode of treatment than solely attenuating VEGF levels.
Celecoxib is an anti-inflammatory drug approved for the clinical treatment of adult arthritis. It also has been used in the treatment of various cancers and is currently being investigated for ocular disorders such as AMD and DR due to its anti-proliferative and anti-VEGF effects [24, 34, 35] . The molecular mechanisms underlying its inhibitory effects are still unclear. A growing body of experimental evidence suggests that NS398, another COX-2 inhibitor, targets HIF-1 activation and blocks tumor growth [36] . A study by Rismanchi et al. showed that celecoxib can suppress colorectal cancer NV by inhibiting the expression of HIF-1α [37] . In the present study, we investigated whether celecoxib has the same effects in RPE cells. We demonstrated that hypoxic exposure for 12 hr induced a significant increase in the expression levels of HIF-1α and VEGF in D407 cells. When RPE cells were cultured in the presence of different concentrations of celecoxib, the hypoxia-induced transcriptional and post-transcriptional increase in VEGF level was inhibited in a concentration-dependent manner. These findings are consistent with the idea that celecoxib may only function as a VEGF inhibitor under hypoxia [38] . In addition, increasing the concentration of celecoxib had significant inhibitory effects on HIF-1α protein expression. These data clearly signify that the regulation of HIF-1α stability is a key factor in controlling HIF-1α protein levels. Hypoxia induces a rapid redox-sensitive increase in HIF-1 protein stability and transcriptional activity, resulting in the activation of target genes involved in erythropoiesis, glycolysis, and angiogenesis [39] . Celecoxib inhibits VEGF expression partly via a HIF-1α signaling mechanism. Our results are consistent with Palayoor et al. who demonstrated that NSAIDs interfered with HIF1-α protein translation in prostate cancer cells [39] .
An active PI3K/AKT/HIF-1α/VEGF pathway plays a central role in tumorigenesis [40] . Celecoxib is known to inhibit the PI3K/AKT pathway in cancer cell lines [41] . Hence, the PI3K/ AKT signaling pathway has previously been demonstrated to be involved in the hypoxiainduced effects on VEGF and HIF-1α expression in cancer cell lines. Our data demonstrate that LY294002, a potent PI3K inhibitor, completely inhibited the basal protein expression patterns of HIF-1α, indicating that the PI3K/AKT pathway plays an important role in the maintenance of basal HIF-1α protein expression, and this is consistent with a study that showed that the PI3K/AKT pathway is required for the hypoxia-induced expression of HIF-1α and VEGF in laser-induced CNV in rats [42] . Our study found that in RPE cells, the PI3K/AKT pathway was activated in response to hypoxia, suggesting that PI3K/AKT may be a potential therapeutic target for CNV. Pretreating the cells with celecoxib inhibited PI3K/AKT, HIF-1α and VEGF accumulation, which is in accordance with previous observations that celecoxibtreated cancer cell lines exhibit reduced PI3K/AKT pathway activation, decreased HIF-1α and VEGF expression, and increased cell apoptosis and proliferation [19] . Together with previous reports, our study shows that suppression of the PI3K/AKT pathway is essential for celecoxib-induced HIF-1α and VEGF down-regulation in RPE cells.
It should be noted that celecoxib may reduce the elevated HIF-1α and VEGF expression but does not return them to normal, physiological baseline levels. Furthermore, the incomplete inhibition of HIF-1α and VEGF up-regulation suggests that aside from hypoxia, other mediators such as NF-kb-mediated COX-2 gene expression and PGE2 production may also contribute to the increased VEGF expression in ocular vascular disease [43, 44] , and there are other molecular pathways that initiate the hypoxia-induced VEGF expression.
Theoretically, celecoxib should inhibit the expression of COX-2. However, our study found that celecoxib inhibited the PI3K/AKT pathway but up-regulated COX-2 expression, [27] . who reported that PI3K inhibition led to an increased level of COX-2 protein and mRNA stability. PI3K negatively regulates the activation of the p38 pathway, and active p38 signaling is necessary for COX-2 production. This is the reason why celecoxib did not suppress but increased COX-2 expression in our study. The down-regulation of PI3K leads to the up-regulation of COX-2 protein levels. Meanwhile, our results also indicate that under hypoxic conditions, celecoxib inhibits RPE cell proliferation and reduces the expression of VEGF through the PI3K/AKT pathway in a COX-2-independent manner.
Conclusion
Our present study demonstrated that celecoxib inhibited cell growth in a dose-dependent manner. Celecoxib reduced HIF-1α and VEGF protein expression levels, and this effect may be partly mediated through a PI3K/AKT-dependent, COX-2-independent manner. Collectively, celecoxib-induced VEGF suppression is related to the hypoxia-mediated and angiogenesisrelated PI3K/AKT signaling pathway. Further studies are required to elucidate the apoptosis mechanism of this signaling pathway during the celecoxib-induced suppression of VEGF.
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